Role of EECP in Angina


The study demonstrated that 78% of patients had a reduction of ≥1 angina class, and 38% of patients had improvement of at least two classes. At least a 50% reduction in frequency of angina was experienced by 76% of patients as well as improvement in quality-of-life assessment that was sustained for at least 2-years.

A follow-up review in 2008 that followed 1061 patients from the International Institute of Cardiac Treatment  who maintained significant improvements in both weekly anginal events and quality of life at 3-years following completion of EECP therapy, compared with data obtained 1-week post-therapy.

A 5-year, single-center, non-randomized study in 33 patients with coronary artery disease, treated with EECP and grouped as responders vs non-responders found that major adverse cardiovascular events or mortality occured in 6 of 7 patients (86%) in the non-responder group and 6 of 26 patients (23%) in the responder group.

12 The overall 5-year survival of EECP-treated patients was 88%, comparable to that seen with medical and revascularization therapies. At 5-years of follow-up, 64% of patients were alive without interim cardiovascular events or need for revascularization.
 
 

Contact Us

EECP is FDA Approved.

BOOK AN APPOINTMENT

Masina Hospital, Byculla, Mumbai 400027

Call Us Now at

Call Us Now at

+91 98205 44693                  +91 98208 50973

Email Us at

Email Us at

info@mhieecp.com

Mhieecp